Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 21300545)

1.

3,5-diarylazoles as novel and selective inhibitors of protein kinase D.

Gamber GG, Meredith E, Zhu Q, Yan W, Rao C, Capparelli M, Burgis R, Enyedy I, Zhang JH, Soldermann N, Beattie K, Rozhitskaya O, Koch KA, Pagratis N, Hosagrahara V, Vega RB, McKinsey TA, Monovich L.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1447-51. doi: 10.1016/j.bmcl.2011.01.014. Epub 2011 Jan 11.

PMID:
21300545
2.

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3.

Boyd S, Brookfield JL, Critchlow SE, Cumming IA, Curtis NJ, Debreczeni J, Degorce SL, Donald C, Evans NJ, Groombridge S, Hopcroft P, Jones NP, Kettle JG, Lamont S, Lewis HJ, MacFaull P, McLoughlin SB, Rigoreau LJ, Smith JM, St-Gallay S, Stock JK, Turnbull AP, Wheatley ER, Winter J, Wingfield J.

J Med Chem. 2015 Apr 23;58(8):3611-25. doi: 10.1021/acs.jmedchem.5b00352. Epub 2015 Apr 13.

PMID:
25849762
3.

Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.

George DM, Breinlinger EC, Friedman M, Zhang Y, Wang J, Argiriadi M, Bansal-Pakala P, Barth M, Duignan DB, Honore P, Lang Q, Mittelstadt S, Potin D, Rundell L, Edmunds JJ.

J Med Chem. 2015 Jan 8;58(1):222-36. doi: 10.1021/jm500669m. Epub 2014 Jul 7.

PMID:
25000588
4.

Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres.

Xiao D, Zhu X, Sofolarides M, Degrado S, Shao N, Rao A, Chen X, Aslanian R, Fossetta J, Tian F, Trivedi P, Lundell D, Palani A.

Bioorg Med Chem Lett. 2014 Aug 1;24(15):3609-13. doi: 10.1016/j.bmcl.2014.05.024. Epub 2014 May 16.

PMID:
24913714
5.

Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.

El Amrani M, Lai D, Debbab A, Aly AH, Siems K, Seidel C, Schnekenburger M, Gaigneaux A, Diederich M, Feger D, Lin W, Proksch P.

J Nat Prod. 2014 Jan 24;77(1):49-56. doi: 10.1021/np4005745. Epub 2013 Dec 16.

PMID:
24328302
6.

Synthesis and structure-activity relationships of 2-amino-3-carboxy-4-phenylthiophenes as novel atypical protein kinase C inhibitors.

Titchenell PM, Showalter HD, Pons JF, Barber AJ, Jin Y, Antonetti DA.

Bioorg Med Chem Lett. 2013 May 15;23(10):3034-8. doi: 10.1016/j.bmcl.2013.03.019. Epub 2013 Mar 13.

7.

Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.

Jin M, Wang J, Kleinberg A, Kadalbajoo M, Siu KW, Cooke A, Bittner MA, Yao Y, Thelemann A, Ji Q, Bhagwat S, Mulvihill KM, Rechka JA, Pachter JA, Crew AP, Epstein D, Mulvihill MJ.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):979-84. doi: 10.1016/j.bmcl.2012.12.042. Epub 2012 Dec 21.

PMID:
23317569
8.

In vivo activity of an azole series of CCR2 antagonists.

Smethurst CA, Bevan N, Brooks C, Emmons A, Gough PJ, Mookherjee C, Moores K, Peace S, Philp J, Piercy V, Watson SP, Zippoli M.

Bioorg Med Chem Lett. 2012 Dec 1;22(23):7252-5. doi: 10.1016/j.bmcl.2012.09.020. Epub 2012 Sep 23. Erratum in: Bioorg Med Chem Lett. 2013 Jan 1;23(1):382.

PMID:
23079519
9.

A targeted library screen reveals a new inhibitor scaffold for protein kinase D.

Tandon M, Wang L, Xu Q, Xie X, Wipf P, Wang QJ.

PLoS One. 2012;7(9):e44653. doi: 10.1371/journal.pone.0044653. Epub 2012 Sep 18.

10.

4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy.

Liddle J, Bamborough P, Barker MD, Campos S, Chung CW, Cousins RP, Faulder P, Heathcote ML, Hobbs H, Holmes DS, Ioannou C, Ramirez-Molina C, Morse MA, Osborn R, Payne JJ, Pritchard JM, Rumsey WL, Tape DT, Vicentini G, Whitworth C, Williamson RA.

Bioorg Med Chem Lett. 2012 Aug 15;22(16):5222-6. doi: 10.1016/j.bmcl.2012.06.065. Epub 2012 Jun 26.

PMID:
22801646
11.

Structure-based optimization of aminopyridines as PKCθ inhibitors.

Jimenez JM, Davis C, Boyall D, Fraysse D, Knegtel R, Settimo L, Young S, Bolton C, Chiu P, Curnock A, Rasmussen R, Tanner A, Ager I.

Bioorg Med Chem Lett. 2012 Jul 15;22(14):4645-9. doi: 10.1016/j.bmcl.2012.05.114. Epub 2012 Jun 6.

PMID:
22738630
12.

The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.

Lewis RT, Bode CM, Choquette DM, Potashman M, Romero K, Stellwagen JC, Teffera Y, Moore E, Whittington DA, Chen H, Epstein LF, Emkey R, Andrews PS, Yu VL, Saffran DC, Xu M, Drew A, Merkel P, Szilvassy S, Brake RL.

J Med Chem. 2012 Jul 26;55(14):6523-40. doi: 10.1021/jm3005866. Epub 2012 Jul 10.

PMID:
22734674
13.

Potent and selective inhibitors of PI3Kδ: obtaining isoform selectivity from the affinity pocket and tryptophan shelf.

Sutherlin DP, Baker S, Bisconte A, Blaney PM, Brown A, Chan BK, Chantry D, Castanedo G, DePledge P, Goldsmith P, Goldstein DM, Hancox T, Kaur J, Knowles D, Kondru R, Lesnick J, Lucas MC, Lewis C, Murray J, Nadin AJ, Nonomiya J, Pang J, Pegg N, Price S, Reif K, Safina BS, Salphati L, Staben S, Seward EM, Shuttleworth S, Sohal S, Sweeney ZK, Ultsch M, Waszkowycz B, Wei B.

Bioorg Med Chem Lett. 2012 Jul 1;22(13):4296-302. doi: 10.1016/j.bmcl.2012.05.027. Epub 2012 May 17.

PMID:
22672799
14.

Neurohormonal regulation of cardiac histone deacetylase 5 nuclear localization by phosphorylation-dependent and phosphorylation-independent mechanisms.

Haworth RS, Stathopoulou K, Candasamy AJ, Avkiran M.

Circ Res. 2012 Jun 8;110(12):1585-95. doi: 10.1161/CIRCRESAHA.111.263665. Epub 2012 May 10.

15.

Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.

Bussenius J, Anand NK, Blazey CM, Bowles OJ, Bannen LC, Chan DS, Chen B, Co EW, Costanzo S, DeFina SC, Dubenko L, Engst S, Franzini M, Huang P, Jammalamadaka V, Khoury RG, Kim MH, Klein RR, Laird D, Le DT, Mac MB, Matthews DJ, Markby D, Miller N, Nuss JM, Parks JJ, Tsang TH, Tsuhako AL, Wang Y, Xu W, Rice KD.

Bioorg Med Chem Lett. 2012 Mar 15;22(6):2283-6. doi: 10.1016/j.bmcl.2012.01.105. Epub 2012 Feb 2.

PMID:
22342124
16.

5-Aryl-4-carboxamide-1,3-oxazoles: potent and selective GSK-3 inhibitors.

Gentile G, Merlo G, Pozzan A, Bernasconi G, Bax B, Bamborough P, Bridges A, Carter P, Neu M, Yao G, Brough C, Cutler G, Coffin A, Belyanskaya S.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):1989-94. doi: 10.1016/j.bmcl.2012.01.034. Epub 2012 Jan 21.

PMID:
22310227
17.

Design, Synthesis, and Biological Evaluation of PKD Inhibitors.

George KM, Frantz MC, Bravo-Altamirano K, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P.

Pharmaceutics. 2011;3(2):186-228. doi: 10.3390/pharmaceutics3020186.

18.

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).

Kinoshita K, Asoh K, Furuichi N, Ito T, Kawada H, Hara S, Ohwada J, Miyagi T, Kobayashi T, Takanashi K, Tsukaguchi T, Sakamoto H, Tsukuda T, Oikawa N.

Bioorg Med Chem. 2012 Feb 1;20(3):1271-80. doi: 10.1016/j.bmc.2011.12.021. Epub 2011 Dec 22.

PMID:
22225917
19.

Structure-activity relationship and pharmacokinetic studies of sotrastaurin (AEB071), a promising novel medicine for prevention of graft rejection and treatment of psoriasis.

Wagner J, von Matt P, Faller B, Cooke NG, Albert R, Sedrani R, Wiegand H, Jean C, Beerli C, Weckbecker G, Evenou JP, Zenke G, Cottens S.

J Med Chem. 2011 Sep 8;54(17):6028-39. doi: 10.1021/jm200469u. Epub 2011 Aug 8.

PMID:
21797275
20.

Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors.

Caldarelli M, Angiolini M, Disingrini T, Donati D, Guanci M, Nuvoloni S, Posteri H, Quartieri F, Silvagni M, Colombo R.

Bioorg Med Chem Lett. 2011 Aug 1;21(15):4507-11. doi: 10.1016/j.bmcl.2011.05.122. Epub 2011 Jun 14.

PMID:
21723120
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk